Research chemicalResearch chemicalBenzodiazepine analogueDepressant

Norflurazepam

Also known as N-Desalkylflurazepam · Desalkylflurazepam

Written by enwyReviewed 4 Aug 20261 sources0 comments

Norflurazepam is a long-acting designer benzodiazepine and an active metabolite shared by several licensed benzodiazepines, including flurazepam. It has appeared as a standalone research chemical. Like other benzodiazepines it is a positive allosteric modulator at GABA-A receptors, producing sedation, anxiolysis and muscle relaxation, with a long half-life that favours accumulation on repeated dosing.

01 Overview

Norflurazepam (N-desalkylflurazepam) is generated in the body as a metabolite of flurazepam, flutoprazepam and related compounds, and is also sold directly as a grey-market benzodiazepine. Its very long elimination half-life means effects and impairment can persist and accumulate across days.

Human pharmacological data specific to norflurazepam as a standalone product are limited to metabolite studies and forensic case reports. Dosing, potency and risk are not well characterised, and product purity in the unregulated market is inconsistent.

02 Mechanism

Positive allosteric modulator at the benzodiazepine site of GABA-A receptors, enhancing chloride conductance and increasing inhibitory GABAergic neurotransmission.

03 Dosing

Tier	Dose	Route	Notes
Light	2–5 mg	Oral	Anecdotal.
Common	5–15 mg	Oral	Anecdotal ranges only; long half-life causes day-to-day accumulation.

04 Effects

Effect	Magnitude	Evidence
AnxiolysisReduction in anxiety typical of benzodiazepines.		Anecdotal
SedationDrowsiness and reduced arousal, often prolonged.		Anecdotal
Muscle relaxationSkeletal muscle relaxation.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Dependence and withdrawalTolerance, physical dependence and a protracted withdrawal syndrome including rebound anxiety, insomnia and seizure risk.	Severe	Common with regular use	Anecdotal
Respiratory depressionSuppression of respiratory drive, markedly increased when combined with opioids or alcohol.	Life-threatening	Uncommon alone, higher with CNS depressants	Anecdotal
Prolonged sedation and impairmentNext-day and cumulative sedation, impaired coordination and memory due to long half-life.	Moderate	Common	Anecdotal

06 Legal status

United States

Not federally scheduled by name

May be treated as a controlled substance analogue under the Federal Analogue Act. · as of Jan 2026

United Kingdom

Class C

Covered by the generic benzodiazepine control. · as of Jan 2026

07 References

Designer benzodiazepines: a review of published dataDrug Testing and Analysis

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.